MedTrace Logo

MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

NCT03675139 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 471

Last updated 2023-02-17

No results posted yet for this study

Summary

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

Conditions

  • Endometrial Hyperplasia Without Atypia

Interventions

DRUG

Medroxyprogesterone Acetate

At a dosage of 10mg/day

DRUG

Dydrogesterone 10 MG

At a dosage of 20 mg/day

Sponsors & Collaborators

  • Xiaojun Chen

    lead OTHER

Principal Investigators

  • Xiaojun Chen, PhD · Obstetrics & Gynecology Hospital of Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-26
Primary Completion
2022-05-14
Completion
2022-05-15

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03675139 on ClinicalTrials.gov